Skip to main content

Cowan Elvia's Form 4 filing

Vaxcyte, Inc. (PCVX) · filed Mar 18, 2026

Accession no.
0001960048-26-000005
Filed
Mar 18, 2026
Trade date
Mar 17, 2026
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions. Open-market sales total $105.2K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Cowan ElviaCIK 0001960048Officer (SVP, Finance & CAO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 17, 2026Common StockSSaleDisposed−1,487$55.39F2−$82,364.9329,380Direct
Mar 17, 2026Common StockSSaleDisposed−405$56.26F3−$22,785.328,975Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported is a weighted-average price. The shares were sold at prices ranging from $54.98 to $55.935. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

The price reported is a weighted-average price. The shares were sold at prices ranging from $56.00 to $56.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)